Inspection Record

Queens Express Pharmacy — FDA 483 Findings

US FDAInspected 2016-08-22Published 2024-01-17 5 findingsAseptic processing and sterility assuranceStability and storageTraining and personnel

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient will regarding the system for monitoring environmental conditions.

3Stability and storage

Drug products are not stored under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected.

4Training and personnel

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

5Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Queens Express Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search